Literature DB >> 16699769

Topography of cerebral monoamine transporter availability in families with SCA2 mutations: a voxel-wise [123I]beta-CIT SPECT analysis.

Christoph Scherfler1, Sylvia M Boesch, Eveline Donnemiller, Klaus Seppi, Helga Weirich-Schwaiger, Georg Goebel, Irene Virgolini, Gregor K Wenning, Werner Poewe.   

Abstract

PURPOSE: The purpose of this study was to investigate the monoamine transporter status of dopamine, serotonin and norepinephrine throughout the brain in spinocerebellar ataxia type 2 (SCA2). To this end, nine patients were studied with [(123)I]beta-CIT SPECT.
METHODS: Data were compared with ten age-matched healthy control subjects and ten patients with young-onset Parkinson's disease (YOPD), matched for age. Parametric SPECT images of the specific-to-non-displaceable equilibrium partition coefficient (V (3)''), which is proportional to the receptor density (B (max)), were generated. In order to objectively localise focal changes in beta-CIT uptake throughout the brain volume without having to make an a priori hypothesis as to their location, statistical parametric mapping (SPM) was applied to SPECT images. Data clusters revealed by SPM, showing significant differences in V (3)'' values between groups, were transformed onto the individual V (3)'' image to obtain mean regional uptake values.
RESULTS: Both SCA2 and YOPD patients showed significant decreases in striatal [(123)I]beta-CIT SPECT uptake when compared with controls. However, in SCA2 patients, additional reductions in caudate/anterior putamen, midbrain and pons [(123)I]beta-CIT uptake were localised with SPM.
CONCLUSION: Voxel-wise analysis of [(123)I]beta-CIT SPECT revealed more widespread decline of monoamine transporter availability in SCA2 than in YOPD, reflecting differences in the underlying pathology. We suggest that the quantification of midbrain and pons [(123)I]beta-CIT signal is likely to improve the diagnostic accuracy in patients presenting with clinical features of both SCA2 and YOPD at initial investigation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16699769     DOI: 10.1007/s00259-006-0104-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  35 in total

1.  Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [125I]PE2I.

Authors:  H Hall; C Halldin; D Guilloteau; S Chalon; P Emond; J Besnard; L Farde; G Sedvall
Journal:  Neuroimage       Date:  1999-01       Impact factor: 6.556

2.  Effect of spatial resolution on SPECT quantification values.

Authors:  A Kojima; M Matsumoto; M Takahashi; Y Hirota; H Yoshida
Journal:  J Nucl Med       Date:  1989-04       Impact factor: 10.057

3.  Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging.

Authors:  W Pirker; S Asenbaum; M Hauk; S Kandlhofer; J Tauscher; M Willeit; A Neumeister; N Praschak-Rieder; P Angelberger; T Brücke
Journal:  J Nucl Med       Date:  2000-01       Impact factor: 10.057

4.  beta-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo.

Authors:  W Pirker; S Asenbaum; S Kasper; H Walter; P Angelberger; G Koch; A Pozzera; L Deecke; I Podreka; T Brücke
Journal:  J Neural Transm Gen Sect       Date:  1995

5.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

Review 6.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

Authors:  W R Gibb; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

7.  [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane: high-affinity SPECT radiotracer of monoamine reuptake sites in brain.

Authors:  J L Neumeyer; S Y Wang; R A Milius; R M Baldwin; Y Zea-Ponce; P B Hoffer; E Sybirska; M al-Tikriti; D S Charney; R T Malison
Journal:  J Med Chem       Date:  1991-10       Impact factor: 7.446

8.  The dosimetry of iodine-123 labelled 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane.

Authors:  J T Kuikka; K A Bergström; A Ahonen; E Länsimies
Journal:  Eur J Nucl Med       Date:  1994-01

9.  A new model for separation between brain dopamine and serotonin transporters in 123I-beta-CIT SPECT measurements: normal values and sex and age dependence.

Authors:  Erik Ryding; Mats Lindström; Björn Brådvik; Martin Grabowski; Peter Bosson; Lil Träskman-Bendz; Ingmar Rosén
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-03-11       Impact factor: 9.236

10.  Autosomal dominant cerebellar ataxia type I in Martinique (French West Indies). Clinical and neuropathological analysis of 53 patients from three unrelated SCA2 families.

Authors:  A Dürr; D Smadja; G Cancel; A Lezin; G Stevanin; J Mikol; R Bellance; G G Buisson; H Chneiweiss; J Dellanave
Journal:  Brain       Date:  1995-12       Impact factor: 13.501

View more
  1 in total

Review 1.  Neuroimaging Biomarkers in SCA2 Gene Carriers.

Authors:  Mario Mascalchi; Alessandra Vella
Journal:  Int J Mol Sci       Date:  2020-02-04       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.